Tharimmune Stock Soars 30% After $540M Funding for Canton Coin Treasury Strategy

Tharimmune shares experienced a significant 30% surge following the company's successful $540 million capital raise. The substantial funding is designated to establish and develop the Canton Coin Treasury Strategy, marking a major strategic move for the pharmaceutical-biotech firm. This capital infusion demonstrates strong investor confidence and positions Tharimmune for accelerated growth in the digital asset treasury space.